9 citations
,
January 2004 in “Journal of dermatological treatment” Rifampicin effectively treated tufted hair folliculitis with no relapse after one year.
2 citations
,
July 1996 in “Annals of Internal Medicine” Taking fluconazole for fungal infections might cause hair loss after about 3 months.
September 2025 in “Clinical and Experimental Rheumatology” 16 citations
,
August 2023 in “JAAD Case Reports” JAK inhibitors, like ruxolitinib, may effectively treat frontal fibrosing alopecia.
December 2025 in “Pediatric Dermatology” Trametinib can cause skin issues, but they can often be managed without stopping the drug.
December 2022 in “Pakistan Journal of Medical and Health Sciences” Tofacitinib effectively treats Alopecia Areata.
April 2025 in “International Journal of Dermatology” Filgotinib completely reversed hair loss in a patient with rheumatoid arthritis and alopecia universalis.
December 2025 in “Current Issues in Molecular Biology” Cytarabine can cause multiple organ toxicities, especially neurotoxicity, but better research methods are needed to fully understand and predict these effects.
August 2020 in “Ugeskrift for Læger” A man with severe hair loss regrew all his hair using tofacitinib and stayed healthy for a year.
March 2025 in “Indian Journal of Dermatology Venereology and Leprology” Tofacitinib is effective for treating alopecia totalis and universalis, with some patients experiencing significant hair regrowth.
January 2024 in “Journal of Clinical Rheumatology and Immunology” Monitor for early signs of myelosuppression, like hair loss, in patients on azathioprine to manage side effects.
April 2024 in “Clinical and experimental dermatology” Tofacitinib is effective for severe alopecia areata, similar to oral betamethasone.
2 citations
,
March 2019 in “PubMed” Fusidic acid successfully treated a rare scalp infection with hair regrowth and no recurrence after 6 months.
January 2016 in “Chemistry & Industry” Two drugs, tofacitinib and ruxolitinib, may help regrow hair by activating hair follicles.
4 citations
,
December 2020 Methotrexate may help stabilize frontal fibrosing alopecia.
17 citations
,
June 2020 in “British Journal of Dermatology” Oral mTOR inhibitors often cause skin and hair side effects but usually don't require stopping treatment.
May 2025 in “The Journal of Rheumatology” Anifrolumab may help improve symptoms in patients with overlapping autoimmune diseases.
Anifrolumab improves quality of life and reduces steroid use in lupus patients.
June 2024 in “Archives of Medical Science” Telitacicept effectively improved hair regrowth in a woman with lupus and alopecia.
May 2026 in “Bioorganic Chemistry”
January 2023 in “National Journal of Physiology, Pharmacy and Pharmacology” Tofacitinib effectively reduced hair loss in alopecia areata patients without adverse effects.
November 2015 in “Clin-Alert” Some medications and supplements can cause serious side effects, including hair loss, heart rhythm problems, liver injury, and other health issues.
October 2022 in “Journal of experimental and clinical medicine” Repurposing existing drugs for COVID-19 shows promise but requires more research to confirm effectiveness.
March 2023 in “PARIPEX INDIAN JOURNAL OF RESEARCH” Tofacitinib helped regrow hair in most patients with severe hair loss.
1 citations
,
June 2022 in “International Journal of Infectious Diseases” A fungal infection was successfully treated with oral and topical antifungals after being misdiagnosed and worsened by corticosteroids.
5 citations
,
January 2023 in “IDCases” Albendazole and praziquantel can cause severe side effects, especially with prolonged use or liver issues.
2 citations
,
April 2024 in “Dermatology Practical & Conceptual” Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.
May 2025 in “CPT Pharmacometrics & Systems Pharmacology” A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
July 2024 in “Reactions Weekly”
October 2009 in “Reactions Weekly” A woman developed lupus after taking hydroxyurea for two years.